10:09 AM
 | 
May 03, 2019
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

GT Biopharma leveraging NK cells to treat HIV

GT Biopharma is expanding its immuno-oncology platform into HIV thanks to work by its partner suggesting the company's TriKE modality could move the needle from life-long therapies to cures.

GT Biopharma Inc. (Pink:GTBP) said April 24 it will develop an HIV program using HIV-targeted Trispecific Killer Engagers (TriKEs) crafted by its long-time partners at the University...

Read the full 258 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >